The Department of Biology at MIT is pleased to host Millennium Day on Tuesday, November 6, 2007. Please join us for the day's featured speaker, Dr. Mark Rolfe, Ph.D., Vice President of Oncology Biology. His talk is titled Discovery of MLN4924, A Novel, First-in-class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer; Dr. Rolfe will speak at the Broad Institute Auditorium, N30-1154, 11 a.m.

Dr. Rolfe graduated from Oxford University with his B.A. in 1982, and received his Ph.D. in 1985 at the National Institute for Medical Research in Mill Hill, London, in the Genetics Laboratory headed by Dr. Robin Holliday FRS, where he studied DNA damage-inducible responses in yeast. Following a three year Postdoctoral Fellowship studying the mechanisms of DNA amplification at the Imperial Cancer Research Fund in George Stark’s laboratory, Dr. Rolfe was awarded a Lucille P. Markey Visiting Fellowship to Columbia University College of Physicians and Surgeons, Department of Genetics and Development, in the laboratory of Dr. Rodney Rothstein. He joined Millennium in December 1999. as Associate Director, Oncology Cell Biology.

Biology and Millenium envision a long and mutually successful relationship encouraging a flow of knowledge and resources.

About Millennium Pharmaceuticals
Founded in early 1993, Millennium Pharmaceuticals, Inc. is a leading  biopharmaceutical company, focused on the discovery and development  of small molecule, biotherapeutic and predictive medicine products. Millennium applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of  delivering personalized medicine. Through the industrialization of  this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. 

For further information, please contact Linda K. Earle at lkn [at] mit.edu.